Antibodies play an essential role in host defence against pathogens by recognizing
microorganisms or infected cells. Although preventing pathogen entry is one potential …

Neutralizing antibodies (nAbs) are being increasingly used as passive antiviral reagents in
prophylactic and therapeutic modalities and to guide viral vaccine design. In vivo, nAbs can …

Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …

The latent viral reservoir is the critical barrier for the development of a cure for HIV-1
infection. Previous studies have shown direct antiviral activity of potent HIV-1 Env-specific …

Monoclonal antibody 10-1074 targets the V3 glycan supersite on the HIV-1 envelope (Env)
protein. It is among the most potent anti-HIV-1 neutralizing antibodies isolated so far. Here …

Background The discovery of potent and broadly neutralizing antibodies (bNAbs) against
human immunodeficiency virus (HIV) has made passive immunization a potential strategy …

HIV-1 immunotherapy with a combination of first generation monoclonal antibodies was
largely ineffective in pre-clinical and clinical settings and was therefore abandoned …

Interruption of combination antiretroviral therapy (ART) in HIV-1-infected individuals leads to
rapid viral rebound. Here we report the results of a phase IIa open label clinical trial …

During hepatitis B virus (HBV) infection, the presence of HBV-specific antibody producing B
cells and functional HBV-specific T cells (with helper or cytotoxic effects) ultimately …

HIV employs multiple means to evade the humoral immune response, particularly the
elicitation of and recognition by broadly neutralizing antibodies (bnAbs). Such antibodies …